Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01476839 · ClinicalTrials.gov registry record · Phase 1
Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma
A Phase 1 study of Recurrent Adult Hodgkin Lymphoma, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT01476839: Completed Phase 1 study of Recurrent Adult Hodgkin Lymphoma, sponsored by City of Hope Medical Center.
NCT01476839 is a Phase 1 study of Recurrent Adult Hodgkin Lymphoma that has completed, run by City of Hope Medical Center. The registered enrollment target is 25 participants, below the 29-participant average among 4 other Recurrent Adult Hodgkin Lymphoma trials with a reported enrollment target (14% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01476839, a Phase 1 study of Recurrent Adult Hodgkin Lymphoma, has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I clinical trial studies the side effects and best dose of radiolabeled monoclonal antibody therapy when given together with combination chemotherapy before stem cell transplant and to see how well it works in treating patients with primary refractory (did not respond to treatment) or relapsed (returned after treatment) Hodgkin lymphoma. Radiolabeled monoclonal antibodies can find cancer cells and carry cancer-killing substances to them without harming normal cells. Drugs used in chemotherapy, such as carmustine, etoposide, cytarabine, and melphalan (BEAM), work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or stopping them from spreading. Giving radiolabeled monoclonal antibody therapy together with combination chemotherapy may kill more cancer cells
Primary Outcome
RP2D will generally be the highest maximum tolerated dose (MTD), but it may be less than the MTD based on a review of available data/cumulative toxicities. Additional pulmonary toxicity monitoring will be performed among enrolled/treated patients with prior brentuximab vedotin exposure for both portions of the study.
Conditions Studied
Interventions
- DRUG etoposide
- DRUG melphalan
- DRUG carmustine
- DRUG cytarabine
- BIOLOGICAL basiliximab
Study Locations (1)
California
- City of Hope Medical Center - Duarte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2012-11-09 |
| Est. Completion | 2024-05-31 |
| Phase | Phase 1 |
What the finished NCT01476839 record still lists
NCT01476839 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 29-participant average among 4 other Recurrent Adult Hodgkin Lymphoma trials with a reported enrollment target (14% lower).
The record links to 1 condition, with Recurrent Adult Hodgkin Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which etoposide is the first listed.
NCT01476839 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT01476839 about?
NCT01476839 is a clinical study titled "Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma". This phase I clinical trial studies the side effects and best dose of radiolabeled monoclonal antibody therapy when given together with combination chemotherapy before stem cell transplant and to see how well it works in treating patients with primary refractory (did not respond to treatment) or rel...
What is the current status of trial NCT01476839?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2012-11-09. Estimated completion is 2024-05-31.
What conditions does trial NCT01476839 study?
This clinical trial studies the following conditions: Recurrent Adult Hodgkin Lymphoma.
What interventions are being tested in trial NCT01476839?
The interventions under investigation include: etoposide (DRUG), melphalan (DRUG), carmustine (DRUG), cytarabine (DRUG), basiliximab (BIOLOGICAL).
Who is sponsoring clinical trial NCT01476839?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01476839 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Adult Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant
ACTIVE NOT RECRUITING · Phase 1
-
Bendamustine Hydrochloride, Rituximab, Etoposide, and Carboplatin in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma or Hodgkin Lymphoma
COMPLETED · Phase 1
-
SGN-30 and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
COMPLETED · Phase 2
-
Vorinostat in Treating Patients With Relapsed or Refractory Advanced Hodgkin's Lymphoma
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI